Chong Kun Dang Pharmaceutical Corp.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment Patients
Phase 4
Not yet recruiting
- Conditions
- Vascular Cognitive Impairment
- Interventions
- Drug: Placebo of Choline Alfoscerate 400mgDrug: Choline Alfoscerate 400mg
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 418
- Registration Number
- NCT05050604
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Retrospective Study to Evaluate the Safety of Duvie in Korean Patients With Type 2 Diabetes Mellitus
Completed
- Conditions
- Type2 Diabetes
- Interventions
- Drug: Duvie(Lobeglitazone) tab 0.5mg
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 2228
- Registration Number
- NCT05043467
- Locations
- 🇰🇷
Division of Endocrinology and Metabolism, Department of Internal Medicine, Bucheon St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
Phase 4
Not yet recruiting
- Conditions
- Mild Cognitive Impairment
- Interventions
- Drug: PlaceboDrug: Choline Alfoscerate
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 418
- Registration Number
- NCT05041790
- Locations
- 🇰🇷
Asan Medical Center Institutional Review Board, Seoul, Korea, Republic of
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mg
Phase 1
Completed
- Conditions
- Hypertension and Dyslipidemia
- Interventions
- Drug: CKD-386(2)Drug: D013, D326, D337
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 60
- Registration Number
- NCT04987970
- Locations
- 🇰🇷
H plus Yangji hospital, Seoul, Korea, Republic of
Clinical Study to Compare the Pharmacokinetics and Safety of D113 With CKD-349 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Chronic Renal Failure
- Interventions
- Drug: CKD-349 F1 Tab.Drug: CKD-349 F2 Tab.Drug: D113 Tab.
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 25
- Registration Number
- NCT04952506
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Korea, Republic of
Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fasting Conditions
Phase 1
- Conditions
- Cardiovascular Diseases
- Interventions
- Drug: CKD-385Drug: D744
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2021-05-28
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 52
- Registration Number
- NCT04906798
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of
Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fed Conditions
Phase 1
- Conditions
- Cardiovascular Diseases
- Interventions
- Drug: CKD-385Drug: D744
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2021-05-28
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 52
- Registration Number
- NCT04906785
- Locations
- 🇰🇷
National University Hospital, Jeonju, Korea, Republic of
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(2)
Phase 1
Completed
- Conditions
- Hypertension and Dyslipidemia
- Interventions
- Drug: CKD-348(2)Drug: CKD-828, D097, D337
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 62
- Registration Number
- NCT04883658
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314
Phase 3
- Conditions
- COVID-19 Pneumonia
- Interventions
- Drug: CKD-314+SOCDrug: CKD-314 Placebo+SOC
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 586
- Registration Number
- NCT04871646
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: CKD-398Drug: CKD-501, D745
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT04869800
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath